Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Int J Cancer
; 153(5): 1080-1095, 2023 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-37293858
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Interferon Type I
/
Melanoma
Limits:
Humans
Language:
En
Journal:
Int J Cancer
Year:
2023
Document type:
Article
Affiliation country:
Italy